Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo.
about
PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasmsNuclear targeting of IGF-1 receptor in orbital fibroblasts from Graves' disease: apparent role of ADAM17Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology GroupInhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approachInsulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer.Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma.Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma.Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRα/β.Neuroblastoma: developmental biology, cancer genomics and immunotherapy.Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group.Targeting the insulin-like growth factor-1 receptor in human cancer.Cell survival signaling in neuroblastoma.AKT pathway in neuroblastoma and its therapeutic implication.A dual-specific anti-IGF-1/IGF-2 human monoclonal antibody alone and in combination with temsirolimus for therapy of neuroblastoma.The role of IGF-1R in pediatric malignancies.Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivinGrowth factors as active participants in carcinogenesis: a perspective.Type I insulin-like growth factor receptor signaling in hematological malignancies.Molecular mechanisms of chemoresistance in osteosarcoma (Review).Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors.The type 1 insulin-like growth factor receptor signalling system and targeted tyrosine kinase inhibition in cancer.New strategies in refractory and recurrent neuroblastoma: translational opportunities to impact patient outcome.PI3K/PTEN/Akt pathway status affects the sensitivity of high-grade glioma cell cultures to the insulin-like growth factor-1 receptor inhibitor NVP-AEW541.Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance.Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells.Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cells.Relationship between insulin-like growth factor-1 receptor and human papillomavirus in patients with oropharyngeal cancer.Targeted medical therapy of biliary tract cancer: recent advances and future perspectives.Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: recent advances and future perspectives.Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer.
P2860
Q26862544-7AC3D6C3-424D-42FF-A0E7-609B9B6BB4C2Q28730668-153B2A86-6101-46A1-A558-A8639986FDA9Q33398810-F52B3A0E-0417-4870-8E64-A438622A3678Q33925323-A97019DA-E3AD-446F-96C9-08616551440EQ34391968-F3852CE7-4841-44E0-B974-BF56FBBF9F4BQ34442835-7897E96D-39E1-4AB1-BF95-B7AF213456B5Q35070321-4D4EB7B2-2285-4EC6-8318-FC205DF06407Q35177853-E27F7AA1-DECC-4F9C-9B39-000288172D33Q35283020-93FF0DB8-3EAE-483E-9E16-A6E9B71735CEQ35880614-D894061D-32A6-4ACE-A311-9E8CD036CC67Q36708178-0EE19716-CF94-40E7-8D62-A8B1859F7AEFQ37010166-0063C5A9-3D46-4DFD-A1C6-E756B8B53DD8Q37159523-39AFE7EA-ACA7-439B-8A71-333B4FBD3F1AQ37162205-569B4C01-E3F1-48D3-AEB3-2D3CDA36985BQ37290912-8E4D5963-8288-4D2F-8B08-2B1CD2EB7A58Q37438760-94BC250E-FF66-4BC7-8E0C-C2BACB4610EDQ37676697-D5DB18A4-4DBB-43D8-8154-E50457429290Q37702186-809404E6-1A19-4349-84A4-EC00A83BD1A4Q37719938-20DE4BD6-E89E-4835-B87D-C33FF3485841Q37838801-CE5C6A43-A9E4-4E17-B6F3-4DC2A177D46AQ38097400-FE2A38C7-E6F3-4189-8B43-04D9A1ACD555Q39639490-9D80FEF0-CCFB-4B9B-A728-EF1F792C556FQ39717036-490395D6-2C26-4741-BEE1-B193CDC49B29Q39753305-EA2C7A72-C4B3-4C77-A138-D9218DB65DCEQ39959245-D286A6F9-BC8B-4B96-851C-1033A177C25AQ41134064-81EB3C43-E76F-425E-8737-D16289F64EA5Q42226895-F384DC27-5352-4FC9-9901-DE2DE4873EE8Q42635172-02E58C55-7C55-4CB4-9B4B-9B795B340BC1Q43097453-CDB357FB-5F62-438A-B57E-C585B89BF644Q43141124-3859BF0C-3D74-4D9B-88C2-C38AF0AF0A4A
P2860
Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Down-regulation of insulin-lik ...... ma cells in vitro and in vivo.
@en
Down-regulation of insulin-lik ...... ma cells in vitro and in vivo.
@nl
type
label
Down-regulation of insulin-lik ...... ma cells in vitro and in vivo.
@en
Down-regulation of insulin-lik ...... ma cells in vitro and in vivo.
@nl
prefLabel
Down-regulation of insulin-lik ...... ma cells in vitro and in vivo.
@en
Down-regulation of insulin-lik ...... ma cells in vitro and in vivo.
@nl
P2093
P1476
Down-regulation of insulin-lik ...... ma cells in vitro and in vivo.
@en
P2093
Barbara Tanno
Camillo Mancini
Carlo Dominici
Giuseppe Raschellà
Heather P McDowell
Mariateresa Mancuso
P304
P356
10.1158/1078-0432.CCR-06-1479
P407
P577
2006-11-01T00:00:00Z